search
Back to results

Intrauterine Adhesion Rate After Hysteroscopic Myomectomy and Application of HYALOBARRIER Gel (HYGEM)

Primary Purpose

Myoma

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
HYALOBARRIER Gel
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Myoma focused on measuring Uterine synechiae, HyalobarrierR Gel Endo, Operative hysteroscopy, submucous myoma

Eligibility Criteria

18 Years - 45 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • 18 to 45 aged-patients
  • hysteroscopic diagnosis of one submucous myoma with less than 3cm diameter requiring operative hysteroscopy with saline type 0, 1 or 2
  • negative plasmatic βHCG test
  • non opposition
  • patients with social security

Exclusion Criteria:

  • multiple submucous myomas type 0, 1 or 2
  • presurgical embolization
  • presurgical impregnation with GnRH agonist
  • coagulative disorders
  • malignancies
  • uncontrolled diabetes
  • operative hysteroscopy with glycine
  • known hypersensitivity to HyalobarrierR Gel Endo
  • infection of the surgical area concerned

Sites / Locations

  • Service de Gynecologie-Obstetrique, Hopital Lariboisière

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

1

Arm Description

For each patient, the HYALOBARRIER Gel was introduced into the uterine cavity with the canula after hysteroscopic myomectomy procedure

Outcomes

Primary Outcome Measures

The formation of postsurgical uterine synechiae rate with HyalobarrierR Gel Endo in hysteroscopic myomectomy

Secondary Outcome Measures

the number of participants with adverse events as a measure of safety and tolerability during the time of the study
Postsurgical fertility with evaluation of number of participants who became pregnant after surgery, spontaneously and/or after assisted reproductive technologies

Full Information

First Posted
May 16, 2011
Last Updated
March 24, 2017
Sponsor
Assistance Publique - Hôpitaux de Paris
search

1. Study Identification

Unique Protocol Identification Number
NCT01412489
Brief Title
Intrauterine Adhesion Rate After Hysteroscopic Myomectomy and Application of HYALOBARRIER Gel
Acronym
HYGEM
Official Title
Prevention of Postsurgical Uterine Synechia With HyalobarrierR Gel Endo in Hysteroscopic Myomectomy : a Prospective Multicenter Study
Study Type
Interventional

2. Study Status

Record Verification Date
March 2017
Overall Recruitment Status
Completed
Study Start Date
August 2011 (Actual)
Primary Completion Date
December 2016 (Actual)
Study Completion Date
December 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the intrauterine adhesion rate after the application of HYALOBARRIER Gel at the end of hysteroscopic myomectomy. Secondary endpoints were tolerance and side effect and subsequent fertility.
Detailed Description
Hysteroscopic myomectomy is the referent surgical treatment for submucous myoma. But intrauterine adhesion rate was evaluated about 7 to 15% after this procedure. The investigators hypothetically believe that application of HYALOBARRIER Gel at the end of the procedure, could be reduce the mean intrauterine rate to 50%. Thus, the investigators performed a multicenter (n = 20) prospective study non randomized in 220 patients with submucous myoma < 3 cm of diameter, evaluated by preoperative ultrasound. The investigators prefer this study design, because the principal reason is the number of enrolled patient were more 200 patients in each group with a double blind randomized study. Now, in all patients, after hysteroscopic myomectomy which performed with a same technique in each center (bipolar coagulation and physiologic serum), a diagnostic hysteroscopy was performed at 2 month to determinate the existence of intrauterine adhesion. Secondary end points were in this study the tolerance and side effects of HYALOBARRIER Gel and the subsequent fertility at 2 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myoma
Keywords
Uterine synechiae, HyalobarrierR Gel Endo, Operative hysteroscopy, submucous myoma

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
189 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
For each patient, the HYALOBARRIER Gel was introduced into the uterine cavity with the canula after hysteroscopic myomectomy procedure
Intervention Type
Device
Intervention Name(s)
HYALOBARRIER Gel
Intervention Description
For each patient, the HYALOBARRIER Gel was introduced into the uterine cavity with the canula after hysteroscopic myomectomy procedure
Primary Outcome Measure Information:
Title
The formation of postsurgical uterine synechiae rate with HyalobarrierR Gel Endo in hysteroscopic myomectomy
Time Frame
between 4 and 8 weeks after initial hysteroscopic myomectomy
Secondary Outcome Measure Information:
Title
the number of participants with adverse events as a measure of safety and tolerability during the time of the study
Time Frame
2 years
Title
Postsurgical fertility with evaluation of number of participants who became pregnant after surgery, spontaneously and/or after assisted reproductive technologies
Time Frame
2 years

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18 to 45 aged-patients hysteroscopic diagnosis of one submucous myoma with less than 3cm diameter requiring operative hysteroscopy with saline type 0, 1 or 2 negative plasmatic βHCG test non opposition patients with social security Exclusion Criteria: multiple submucous myomas type 0, 1 or 2 presurgical embolization presurgical impregnation with GnRH agonist coagulative disorders malignancies uncontrolled diabetes operative hysteroscopy with glycine known hypersensitivity to HyalobarrierR Gel Endo infection of the surgical area concerned
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jean-Louis Benifla, MD, PhD
Organizational Affiliation
Assistance Publique - Hôpitaux de Paris
Official's Role
Principal Investigator
Facility Information:
Facility Name
Service de Gynecologie-Obstetrique, Hopital Lariboisière
City
Paris
ZIP/Postal Code
75010
Country
France

12. IPD Sharing Statement

Learn more about this trial

Intrauterine Adhesion Rate After Hysteroscopic Myomectomy and Application of HYALOBARRIER Gel

We'll reach out to this number within 24 hrs